Our Take
Novel capsids and delivery routes matter less than whether MSH3 targeting actually works better than huntingtin protein suppression.
Why it matters
Gene therapies remain confined to ultra-rare diseases due to high doses, manufacturing costs, and safety risks. Huntington's affects 30,000 Americans, making it a test case for broader market viability.
Do this week
Biotech investors: Track LTS-201's IND filing this year to gauge whether MSH3 targeting produces cleaner preclinical safety data than huntingtin suppression approaches.
Latus secures $97M for MSH3-targeting gene therapy
Latus Bio closed a $97 million Series A round led by 8VC to advance two gene therapies into clinical trials (per company announcement). The funding combines a $54 million initial raise with a $43 million extension.
The company will test LTS-101 for CLN2 Batten disease in Q3 and plans to file an IND for LTS-201 in Huntington's disease later this year. Unlike UniQure's huntingtin protein suppression approach, Latus targets the MSH3 gene, which research suggests could prevent the toxic nucleotide repeat expansions that drive disease progression.
Latus claims its viral capsids enable efficient delivery at lower doses than current gene therapies, potentially reducing manufacturing costs and safety risks. The approach targets neurological conditions initially but extends to kidney, eye, heart, and muscle diseases.
Manufacturing economics limit gene therapy reach
Current gene therapies require high doses and complex manufacturing, restricting use to ultra-rare diseases with small patient populations. Huntington's disease affects roughly 30,000 Americans, representing a significantly larger market than typical gene therapy targets.
The MSH3 pathway offers a different mechanism than direct huntingtin suppression. Published research indicates MSH3 knockdown could halt the repeat expansion process that creates toxic huntingtin protein, rather than cleaning up protein already produced.
UniQure's competing Huntington's gene therapy faces regulatory delays, with the FDA reportedly demanding additional clinical trials before approval consideration. This creates an opening for alternative approaches.
Watch the preclinical safety comparison
Latus claims single-injection durability for LTS-201 based on preclinical data, but the company has not published head-to-head comparisons with huntingtin suppression approaches. The MSH3 target remains less validated than direct huntingtin protein reduction.
The IND filing timing will reveal whether the novel capsids actually deliver measurable dose reductions or represent incremental improvements in delivery efficiency. Lower doses matter most if they translate to reduced manufacturing costs per patient treated.
CLN2 Batten disease provides a smaller-scale test case for the capsid technology before Huntington's trials begin. The Q3 trial start will show whether Latus can execute on clinical development timelines.